93rd European Atherosclerosis Society (EAS) Congress 2025

Key presentations at the recent 93rd Congress of the European Atherosclerosis Society (4-7 May 2025, Glasgow, UK) included a comprehensive review of clinical trials of novel TG-lowering agents, study updates for olezarsen, plozasiran and zodasiran, initial findings with the novel ANGPTL4 antibody, MAR001, and fresh insights on the impact of an ANGPTL3 loss of function […]

Microsomal transfer protein (MTP), apoCIII and ANGPTL3 inhibitors, and a fibroblast growth factor (FGF21) analogue, have all shown efficacy in treating hypertriglyceridaemia (HTG), with TG reductions of approximately 45% to 80% depending on the clinical setting. This was how Professor Marcello Arca (Sapienza University, Rome, Italy) summarised current data at the end of his wide-ranging review of novel approaches to TG lowering.

Olezarsen 80 mg significantly lowers both fasting and postprandial TG level in patients with hypertriglyceridaemia (HTG), with potential anti-atherogenic effects via reduction of residual inflammatory risk. These are the findings from research into postprandial responses to olezarsen reported by researchers from the Netherlands.

Latest data from the Phase 3 PALISADE trial of plozasiran in familial chylomicronaemia syndrome (FCS) have demonstrated quality of life (QoL) improvements associated with previously reported reductions in TG and acute pancreatitis (AP). 

Sustained reductions in LDL-C, apoB and Lp(a) were reported with the ANGPTL3 GalNac RNAi, zodasiran, in patients with homozygous familial hypercholesterolaemia (HoFH) in the GATEWAY trial open label extension (OLE).  

The ANGPTL4 antibody, MAR001, reduces TG and remnant cholesterol (RC) and is generally safe and well tolerated, according to results of single ascending dose and multiple dose studies.